Receiving immunotherapy for the treatment of advanced renal cell carcinoma is associated with higher burden of illness, coagulopathy, cardiac arrhythmia, and disparities.
Saved in:
| Title: | Receiving immunotherapy for the treatment of advanced renal cell carcinoma is associated with higher burden of illness, coagulopathy, cardiac arrhythmia, and disparities. |
|---|---|
| Authors: | Eichhorn S; Boston Medical Center, Boston University School of Medicine, Boston, MA, 02118, USA., Pili R; Department of Medicine, Division of Hematology and Oncology, University at Buffalo, Buffalo, NY, 14203, USA., Epstein JB; City of Hope Comprehensive Cancer Center, Duarte CA and Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical System, Los Angeles, CA, USA., Rajesh R; Nova Southeastern University, Fort Lauderdale, FL, 33328, USA., Satheeshkumar PS; Department of Medicine, Division of Hematology and Oncology, University at Buffalo, Buffalo, NY, 14203, USA. spoolakk@buffalo.edu. |
| Source: | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2025 Mar 15; Vol. 33 (4), pp. 285. Date of Electronic Publication: 2025 Mar 15. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer International Country of Publication: Germany NLM ID: 9302957 Publication Model: Electronic Cited Medium: Internet ISSN: 1433-7339 (Electronic) Linking ISSN: 09414355 NLM ISO Abbreviation: Support Care Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1433-7339 |
|---|---|
| DOI: | 10.1007/s00520-025-09353-5 |
